Life from lifelessness.
1. With two dozen COVID-19 vaccines already in use around the world, a successful efficacy trial of yet another candidate might elicit yawns. But the findings announced by China’s Clover Biopharmaceuticals on 22 September—in a press release and a slide deck full of unusually fine-grained information—stood out. Two doses of Clover’s vaccine, based on a m…
Keep reading with a 7-day free trial
Subscribe to News Items to keep reading this post and get 7 days of free access to the full post archives.